Mark Ogunsusi

Mark Ogunsusi is an associate in the Drug Pricing and 340B Program practice group of Powers Pyles Sutter & Verville.

Mark focuses his practice primarily on regulatory matters involving pharmaceutical pricing and, specifically, the 340B federal drug discount program. In addition to his legal degree, Mark is a doctor of pharmacy. Mark regularly advises an array of healthcare entities on the nuances of the 340B program, the Medicaid drug rebate program, federal pharmacy law, food and drug law, and state pharmacy law. Mark has significant experience in all aspects of the 340B program, including covered entity registrations, contract pharmacy arrangements, patient eligibility determinations, duplicate discount issues, drug inventory management, eligibility requirements, third party vendor arrangements, auditable records requirements, and other 340B program compliance matters. He has over ten years of experience as a pharmacist that inform his health law practice. His other relevant prior experience includes serving as the CEO of PrystM LLC, a healthcare and technology consulting firm.

Prior to attending law school, Mark worked in several different healthcare settings, including at one of the nation’s largest safety-net hospitals.  Mark is a fervent advocate for promoting access to pharmaceutical care and supporting the nation’s safety-net providers. Mark is a co-author of "340B Drug Pricing Program," a chapter in the Health Care Compliance Association's 2021 Complete Healthcare Compliance Manual. Mark earned his J.D. from Georgetown University Law Center and graduated cum laude with a doctorate of pharmacy from Mercer University College of Pharmacy.